Business Overview: NeuroPace, Inc. (NASDAQ: NPCE)

---

Executive Summary

NeuroPace, Inc. is a medical device company focused on epilepsy, headquartered at 455 N. Bernardo Avenue, Mountain View, California. Its flagship and only commercial product, the RNS System, is described in its own SEC filings as the first and only commercially available brain-responsive neuromodulation system — an implanted device that continuously monitors a patient's brain electrical activity, detects that specific patient's abnormal seizure-related patterns, and responds in real time with short electrical pulses designed to stop a seizure before it starts. The RNS System received FDA Premarket Approval (PMA) in late 2013 and began its commercial rollout in early 2014; more than 6,000 patients had received the device as of December 31, 2024.

NeuroPace matters because it occupies a category of one: no other FDA-approved device combines real-time, closed-loop, patient-specific brain monitoring with therapeutic stimulation for epilepsy. Its only named competitors — LivaNova's VNS System and Medtronic's DBS System — are open-loop stimulation devices without NeuroPace's responsive, data-driven detection capability, giving NeuroPace a genuine clinical differentiation story inside a currently small but expanding addressable market (roughly 575,000 U.S. adults with drug-resistant focal epilepsy today, versus a long-term ambition of over 16 million patients globally across broader epilepsy and other brain-disorder indications).

As a commercial-stage company that only reached meaningful scale in the last several years, NeuroPace is still unprofitable and funds growth through a combination of product revenue, dilutive equity raises (including a February 2025 public offering), and disciplined expense management — the central tension in its story is balancing fast revenue growth (+22% in 2024) against the path to sustained profitability.

---

1. Core Business Model & How They Work

NeuroPace sells a complete implantable system plus a connected ecosystem of monitoring and programming software, generating revenue primarily from hospital capital/device purchases (the implant itself) with recurring touchpoints through battery replacement, data services, and its direct distribution of DIXI Medical's Stereo EEG diagnostic products.

   Patient referred to            Implant surgery at a           Ongoing therapy +
   epileptologist/neurosurgeon    Level 4 Comprehensive          continuous brain-data
   at a Comprehensive Epilepsy    Epilepsy Center (CEC) or       capture (iEEG)
   Center (CEC)                    qualified community site
         |                                |                              |
         v                                v                              v
   Clinical workup confirms       NeuroPace neurostimulator       Physician Tablet + PDMS +
   drug-resistant focal           + leads implanted; device       nSight Platform let clinicians
   epilepsy diagnosis             billed via hospital/payor       remotely review data and
                                   (CPT codes for implant)         tune stimulation; ~11-year
                                                                    battery -> replacement revenue

Revenue is earned at implant (device sale to the hospital), and again roughly a decade later at battery-end-of-life replacement (an outpatient procedure that over 90% of eligible patients chose in 2019 data cited by the company), plus distribution revenue from the DIXI Medical Stereo EEG exclusive U.S. distribution agreement used in pre-surgical diagnostic workups.

---

3. Key Offerings

---

4. Competitive Landscape

NeuroPace names exactly two competitors in its own 10-K, both much larger, better-capitalized medical device companies offering alternative — but mechanistically different — neuromodulation therapies:

• LivaNova plc (VNS System) — Vagus Nerve Stimulation; an open-loop device that stimulates on a fixed schedule rather than in response to detected brain activity.
• Medtronic plc (DBS System) — Deep Brain Stimulation; also open-loop, originally developed for movement disorders and later adapted for epilepsy.
• Non-device alternatives: resective or ablative brain surgery, which NeuroPace positions its device against for patients who are not ideal surgical candidates.

                    Responsive / closed-loop (reacts to actual seizure activity)
                                      ^
                                      |
                        NeuroPace RNS *
                                      |
      Device-based  <-----------------+----------------->  Surgical
      neuromodulation                 |                     resection/ablation
                                      |
              LivaNova VNS *    * Medtronic DBS
                                      |
                                      v
                    Open-loop / scheduled or non-specific stimulation

NeuroPace's stated competitive basis is tolerability, efficacy, and access to continuous objective brain data — a direct contrast to LivaNova's and Medtronic's open-loop approaches, which do not generate the same patient-specific diagnostic data stream.

---

5. Strategic Strengths & Risks

Strengths (moat sources):

• Regulatory and IP barriers: 95 issued U.S. patents plus 16 pending applications covering detection algorithms, stimulation methods, and AI-based data analysis, layered on top of the multi-year, costly FDA PMA pathway that any true competitor would need to repeat.
• High switching costs from implantation: Once implanted, a patient's device cannot be casually swapped — explanting and replacing with a competing system requires additional brain surgery, giving NeuroPace an unusually durable, multi-year revenue relationship per patient (reinforced by the ~11-year average battery life and >90% replacement-election rate).
• Breakthrough Device Designation (IGE, Feb. 2021) and an expanding clinical evidence base (82.0% median seizure reduction at 36 months in the FDA-mandated Post-Approval Study; 75% median reduction at nine years in the Long-Term Treatment study) support continued payor coverage and label expansion.
• 2023 PMA supplement widened the prescriber/implanter base beyond Level 4 Comprehensive Epilepsy Centers to roughly 1,800 additional epileptologists, directly expanding the commercially addressable physician base.

Risks:

• Unprofitability and cash burn: Net loss of $27.1 million in 2024 against $79.9 million of revenue; the company depends on continued access to capital (e.g., the February 2025 public offering) to fund growth until profitability.
• Single-product concentration: virtually all revenue depends on one device platform (RNS System); any safety signal, recall, or reimbursement setback would disproportionately affect the whole company.
• Narrow current label and limited international footprint: approved only for adults 18+ with drug-resistant focal epilepsy in the U.S.; pediatric (RESPONSE study) and IGE (NAUTILUS study) label expansions are not yet approved, and the device is not approved for sale outside the U.S. except limited Canadian case-by-case approvals.
• Larger, better-capitalized competitors: both LivaNova and Medtronic have far greater resources, sales infrastructure, and R&D budgets, and could in theory pursue responsive/closed-loop features of their own.

---

6. Financial Overview

---

7. Summary Conclusion

NeuroPace's moat rests on a rare combination for a small-cap medtech company: genuine clinical differentiation (closed-loop, brain-responsive stimulation that no competitor currently replicates), a deep patent portfolio, and — most importantly — the structural switching costs created by surgical implantation itself, which make a NeuroPace patient a multi-year, effectively locked-in customer. The biggest forward risk is not competitive displacement in the near term, but execution and capital risk: NeuroPace must keep growing fast enough (and eventually turn profitable) to justify continued equity-market access, while label expansions into pediatric and idiopathic generalized epilepsy populations — both still pending — will determine whether its addressable market meaningfully grows beyond today's ~575,000-patient U.S. base.